Mission Bio's Tapestri Enables Single-Cell Profiling of Residual Disease, Identifying AML Patients Likely to Benefit from Motixafortide in the Multicenter BLAST Trial

Mission Bio's Tapestri Enables Single-Cell Profiling of Residual Disease, Identifying AML Patients Likely to Benefit from Motixafortide in the Multicenter BLAST Trial

Randomized phase II BLAST trial retrospective analysis utilizing the Tapestri™ single-cell multiomic platform of the randomized multicenter phase II BLAST clinical trial identifies high CXCR4 expression on residual leukemic cells as a candidate predictive biomarker for Motixafortide treatment in acute myeloid leukemia (AML) patients, a signal invisible to the standard of care analysis methods used in the original clinical trial.

Mission Bio, a leader in single-cell multiomics, jointly announces with Heidelberg University Hospital, Martin Luther University Halle-Wittenberg, the East German Study Group for Hematology and Oncology (OSHO), and the Study Alliance Leukemia (SAL) findings from a retrospective single-cell analysis of the randomized, double-blind, placebo-controlled phase II BLAST clinical trial in acute myeloid leukemia (AML). The investigator-initiated trial was sponsored by Martin Luther University Halle-Wittenberg, scientifically coordinated and led by Heidelberg University Hospital, and conducted at 29 academic centers in Germany with the active support of OSHO and SAL.